BioSpace News Archive

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has entered into securities purchase agreements with certain institutional investors, led by Altium Capital,

Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19

Repertoire Immune Medicines, a clinical-stage biotech company working to unleash the curative power of the immune system, today announced the addition of three new members to its executive team: Andrea DiFabio, EVP, Chief Legal and Corporate Administration Officer; Tim Harris, Ph.D., Dsc., EVP, Corporate Development and Lucia Celona, EVP, Chief Human Resources Officer.

Dr. Poznansky will answer pre-submitted questions from investors at the conclusion of the call

Novant Health will resume some non-time sensitive and non-emergent surgeries and procedures beginning Monday, May 4. Additionally, clinics will reinstate appointments that were previously delayed by phasing in visits starting with pediatric well checks, chronic disease and acute issue visits.

Quantzig, a global data analytics and advisory firm that delivers actionable analytics solutions to resolve complex business problems, has been actively analyzing the current pharma landscape and the impact of the ongoing crisis on pharmaceutical warehousing and transport.

Jay Shepard to lead Foundation’s efforts to accelerate most promising functional recovery/care research toward cures for people living with paralysis

Containing an invisible enemy, a pandemic virus, becomes increasingly difficult, if not impossible, when the virus can remain presymptomatic for days.

The lack of sensation that accompanies paralysis is an additional burden that has, until now, been a problem that science has not been able to remedy.

Yiling Pharmaceutical announced that Lianhua Qingwen capsules have been added to the “Novel Coronavirus Pneumonia Diagnosis and Treatment Scheme for Laos” as the fourth traditional Chinese medicine to treat COVID-19 pneumonia in Laos.